Healthcare News and Headlines
Healthcare News and Headlines
Johnson & Johnson MedTech launched three new stroke devices—Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 delivery aid—expanding its aspiration‑first portfolio. The catheters feature a multi‑axial shaft, radiopaque tips and hydrophilic coating to improve navigation of distal clots. Innerglide 7 provides extra support for large‑bore catheters like Cereglide 71. The products are rebranded from the former Cerenovus line, unifying J&J’s neurovascular offerings.
Bioxytran announced positive phase 1b/2a data for its oral antiviral ProLectin‑M in a randomized, double‑blind, placebo‑controlled trial of 39 mild‑to‑moderate COVID‑19 patients in India. The highest dose (16,800 mg/day) achieved viral clearance in 90% of participants by day 5 versus 20% on placebo,...
The Center for Innovation & Value Research launched the Rare Disease Patient Engagement (RDPE) Guidance and Checklist, a practical toolkit to embed patient and caregiver input throughout rare‑disease comparative effectiveness research, value assessment, and economic modeling. The resource bundles best‑practice...
The article sketches a typical week for a clinical informaticist, showing how patient care, system design, feedback loops, governance, safety, and evidence assessment intertwine. It highlights that a single day can involve everything from bedside interaction to long‑term technology strategy....
The large‑cap pharmaceutical sector is rebounding in 2026 after a muted 2025, buoyed by strong quarterly results, aggressive M&A, and robust pipeline activity. Zacks ranks the industry at #172, but it posted a 10.8% gain over the past year, outpacing...
The European Union has granted approval for Vueway (gadopiclenol) to be used in neonates, infants, and toddlers, marking a pivotal expansion of pediatric MRI contrast agents. Vueway delivers diagnostic‑grade imaging at half the dose of conventional macrocyclic GBCAs, thanks to...
Biotech Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for its Prader‑Willi drug ARD‑101 after routine safety monitoring identified reversible cardiac observations in healthy volunteers receiving supratherapeutic doses. The pause affects both the main trial and an...
Merck and Pfizer’s Keytruda‑Padcev doublet delivered a dramatic survival advantage in the Phase 3 EV‑304 study of muscle‑invasive bladder cancer. The regimen cut the risk of disease progression, recurrence or death by 47% compared with gemcitabine‑cisplatin and lowered overall‑mortality risk by...
The GAO report finds that the Department of Health and Human Services (HHS) administers Sexual Risk Avoidance Education (SRAE) grants but relies mainly on near‑term performance measures focused on program reach rather than youth outcomes. While HHS reviews curricula for...
Tuesday Health has partnered with Buckeye Health Plan to extend its palliative‑care model across Ohio, reaching the plan’s 400,000 Medicaid, Medicare and Marketplace members. The collaboration delivers an interdisciplinary team—including nurses, social workers, NPs and physicians—through in‑person, hybrid and virtual...
Chinese drugmakers, led by Jiangsu Hengrui Pharmaceuticals, are emerging as global biotech contenders. Hengrui topped 2024 trial sponsorship, boasts a pipeline of 100 investigational drugs and 400 trials, and secured a $500 million partnership with GSK that could yield $12 billion. Analysts...
Harrison.ai filed a citizen petition asking the FDA to grant optional pre‑market exemption for radiology computer‑aided detection (CAD) devices, allowing manufacturers with an existing cleared product to launch similar tools without a new 510(k). The agency must issue a rapid...
Shine Technologies announced a $240 million financing round led by Patrick Soon‑Shiong’s NantWorks, bringing its total capital raised to over $1 billion. The infusion will accelerate the company’s commercial fusion initiatives and expand its Lu‑177 isotope production, a cornerstone of targeted cancer...
Segmed, a leader in real‑world medical imaging, announced a partnership with Verily to make its de‑identified, diagnostic‑grade imaging datasets available on Verily’s AI‑native Pre Exchange and Workbench platforms. The initial offering is a longitudinal breast‑cancer cohort featuring digital breast tomosynthesis...
A new donor‑derived cell‑free DNA (dd‑cfDNA) blood test is transforming post‑transplant surveillance by providing real‑time, noninvasive insight into graft health. The assay quantifies donor DNA fragments released when a transplanted organ is injured, offering a high negative predictive value that...
The U.S. FDA granted accelerated approval to Ascendis’ Yuviwel (navepegritide) for increasing linear growth in children aged two years and older with achondroplasia and open epiphyses. Approval rests on three placebo‑controlled trials and up to three years of open‑label extension...
Employers often rely on isolated claims or EAP call counts, which dramatically understate the true scale of behavioral health issues in the workforce. By aggregating medical, pharmacy, and EAP data—and even website analytics—companies can capture both prevalence and cost, revealing...
An independent NHS evaluation across seven Suffolk care homes using Nobi Smart Lights reported up to a 75% reduction in falls‑related hospital admissions and up to a 65% drop in ambulance call‑outs. The study compared six months of baseline data...
Cell therapy manufacturing is vulnerable to contamination because living cells cannot be terminally sterilized. Regulatory bodies such as EU GMP Annex 1 and the FDA now require risk‑based contamination control strategies that prioritize closed, sterile, and automated processes. Closing open steps...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent (dupilumab) for paediatric chronic spontaneous urticaria (CSU) in children aged 2‑11. The recommendation is based on robust Phase III data from the LIBERTY‑CUPID...
Synergy Spine Solutions received FDA pre‑market approval for its Synergy Disc, a cervical artificial disc designed to preserve motion and correct spinal alignment. Clinical data showed an 87.1% composite success rate at 24 months, with significantly lower neck‑pain and arm‑pain...
Opus Genetics presented early Phase I/II data for its OPGx‑BEST1 gene therapy targeting best vitelliform macular dystrophy and autosomal‑recessive bestrophinopathy. In a sentinel 63‑year‑old participant, the treatment was well tolerated and delivered a 12‑letter gain in best‑corrected visual acuity after...
BioMarin’s enzyme substitution therapy Palynziq received FDA approval for use in adolescents aged 12 and older with phenylketonuria (PKU). The decision was based on Phase III PEGASUS trial results showing 44.4% of participants lowered blood phenylalanine below guideline levels, with a...
The article profiles 18 UK biotech firms spanning oncology, immunology, regenerative medicine and AI‑driven drug design, highlighting recent milestones such as Amphista’s $30 million upfront deal with BMS, Autolus’ FDA and EU approvals for obe‑cel, and Isomorphic Labs’ $600 million raise to...
Kardi Ai, a Czech med‑tech firm, has secured EU MDR Class IIa certification and is expanding its long‑term ECG monitoring platform into the DACH region. The solution records heart rhythm for up to 12 months, uses AI to deliver physician‑ready reports within...
Lewis A. Grossman's book "Choose Your Medicine" traced historic battles over alternative‑medicine freedom, a pattern echoed today as Health Secretary Robert F. Kennedy Jr. pushes to loosen FDA oversight of unapproved stem‑cell and peptide treatments. The interview highlights recurring public resistance...
Researchers have developed a monolithic 3D nanoelectrode array (HD‑NEA) that integrates 26,400 vertical nanowire electrodes directly onto commercial CMOS chips. The low‑temperature wafer‑scale post‑fabrication process maintains circuit functionality while delivering uniform, high‑yield electrode performance across 4‑inch wafers. In vitro recordings...
X4 Pharmaceuticals’ Xolremdi (mavorixafor) received a positive opinion from the European CHMP, recommending approval under exceptional circumstances with an EC decision expected in Q2 2026. The recommendation is based on the global Phase III 4WHIM trial involving 31 patients aged 12 and...
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending conditional approval of Ipsen’s Ojemda (tovorafenib) as monotherapy for pediatric low‑grade glioma with BRAF fusions, rearrangements or V600 mutations. The recommendation is based on...
North American insurers are confronting a surge in claim severity as medical inflation, social inflation, and AI‑generated fraud drive costs upward. The Gallagher Bassett 2026 Carrier Report shows 64% of carriers see more complex claims, with 56% pinpointing rising medical expenses...
Life‑science firms face heightened D&O liability as stock volatility spikes around clinical trial readouts and regulatory decisions. Shareholder lawsuits often begin with books‑and‑records demands that probe whether public statements matched internal knowledge. The article stresses disciplined, consistent disclosure and early...
Healthcare revenue cycle leaders are shifting from rule‑based automation to AI‑driven predictive analytics. Machine‑learning models now scan claim data, documentation and payer behavior to flag denial risks before submission. Early corrections improve first‑pass acceptance, shorten cash cycles and reduce revenue...
Quanterix (QTRX) reported FY 2025 revenue of $16.1 million, down $11 million from the prior year, driven by steep declines in collaboration and contract‑manufacturing income. R&D spending fell modestly to $140.7 million, while SG&A rose to $65.5 million due to higher professional fees for...
Cerus Corp reported record total revenue of $233.8 million in 2025, a 16% increase year‑over‑year, driven by strong product sales and robust growth in EMEA. Product revenue rose 14% for both the quarter and full year, with IFC kit sales...
Researchers integrated inflammatory cytokines, kynurenine pathway balance, and amygdala reactivity with the IDEA‑RS sociodemographic risk score to predict adolescent depression over three years. The composite model (IDEA‑BIO‑RS) raised predictive accuracy from a 0.715 AUC to 0.889, correctly classifying 82.2% of...
Xeris Biopharma reported record Q3 2025 product revenue of $74.1 million, a 40% year‑over‑year increase driven primarily by Recorlev’s 109% revenue jump. The company posted its first quarterly net income and an adjusted EBITDA of $17.4 million, reflecting strong operating leverage and...
The researchers conducted a crowdsourced megastudy that tested 12 digital single‑session interventions (SSIs) for depression among a large U.S. adult sample recruited online. Using a preregistered design, three of the SSIs produced statistically significant reductions in depressive symptoms, with effect...
UniQure reported a regulatory setback as the FDA now deems the Phase 1/2 external‑control data for AMT‑130 insufficient for a Biologics License Application, creating uncertainty around the U.S. filing timeline. Despite this, the high‑dose AMT‑130 achieved a statistically significant 75% slowdown...
UroGen Pharma reported over $127 million in cash at the end of Q4 2025, affirming sufficient liquidity to reach profitability if current plans hold. The company highlighted steady month‑over‑month growth in Zasturi enrollment, with community treatment share now around 35‑40% and institutional...
Senseonics reported a 60% jump in full‑year revenue to $35.3 million and lifted gross margins above 50% after a year of selling the Eversense 365 implantable CGM. The company completed a full transition of commercial operations from Ascensia, eliminating revenue‑sharing and gaining...
Surgery Partners reported Q4 2025 net revenue of $821.5 million, a 6.6% year‑over‑year increase, and adjusted EBITDA of $136.4 million, up 6.1% with a 16.6% margin. The company revised full‑year revenue guidance to $3.275‑$3.30 billion and adjusted EBITDA to $535‑$540 million, citing delayed capital...
Japan’s healthcare system is rapidly expanding multilingual services as inbound tourism surges, with 2,500 hospitals and clinics now listed as foreign‑patient friendly—a 1.6‑fold rise over six years. The Hakuba International Clinic exemplifies the trend, handling 40‑50 walk‑ins daily, 80% of...
Compliance failures are now costing MedTech manufacturers millions, as regulators require deeper traceability, faster reporting, and unified post‑market oversight. Gaps in ERP and QMS integration lead to delayed approvals, recalls, and costly litigation, turning compliance into a direct revenue driver....
A cross‑sectional survey of 210 anaphylaxis patients and caregivers revealed that 90% prefer needle‑free epinephrine delivery, while 89% value devices that are small and easy to carry. Respondents also expressed strong concerns about temperature effects on epinephrine stability. The study...
GoodRx introduced GoodRx Employer Direct, a new service allowing employers to directly subsidize the manufacturer‑sponsored price of high‑cost brand medications such as GLP‑1 drugs without adding them to health‑plan formularies. The model, first piloted with retailer Hy‑Vee, lets employers contribute...
Reverend Jesse Jackson, who died last month, is remembered not only as a civil‑rights icon but also as an early champion of HIV/AIDS awareness. In the 1980s he publicly tested for HIV, urging Black clergy and marginalized communities to confront...
The U.S. Bureau of Labor Statistics’ Consumer Price Index (CPI) omits key out‑of‑pocket healthcare expenses, masking true inflation for many Americans. While the CPI shows a modest 3% rise since President Trump’s second inauguration, premiums on the ACA marketplace have...
Telehealth is moving from an optional service to a routine component of clinical practice, forcing health‑care educators to rethink curricula. The 2024 U.S. Department of Health and Human Services Workforce Research Recap highlights soaring telehealth utilization and a skills gap...
Selective serotonin reuptake inhibitors revolutionized mood‑disorder treatment but often cause sexual side effects. A subset of patients experiences post‑SSRI sexual dysfunction (PSSD), where libido loss, erectile problems and orgasmic difficulties persist months or years after discontinuation. The underlying neurochemical mechanisms...
The authors respond to critiques of their correlational study linking burnout and ethical awareness among mental‑health professionals in Lahore, Pakistan. They acknowledge the purposive, non‑probability sampling limits generalizability but argue it was necessary given fragmented service delivery. Findings showed age...
